These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12132053)

  • 1. Septic shock and multiple organ failure after hematopoietic stem cell transplantation: treatment with recombinant human activated protein C.
    Pastores SM; Papadopoulos E; van den Brink M; Alicea M; Halpern NA
    Bone Marrow Transplant; 2002 Jul; 30(2):131-4. PubMed ID: 12132053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
    Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
    Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alfa (activated) in an infant with gram-negative septic shock.
    Sajan I; Da-Silva SS; Dellinger RP
    J Intensive Care Med; 2004; 19(1):51-5. PubMed ID: 15035755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.
    Rice TW; Bernard GR
    Am J Med Sci; 2004 Oct; 328(4):205-14. PubMed ID: 15486535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Re-administration of drotrecogin alfa activated in a patient with episodes of severe sepsis].
    Verdú MT; Sánchez OJ
    Rev Esp Anestesiol Reanim; 2007 Dec; 54(10):637-8. PubMed ID: 18201006
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of drotrecogin alfa (activated) in two patients with severe sepsis.
    Mikaszewska-Sokolewicz M; Nierebińska M; Mayzner-Zawadzka E
    Med Sci Monit; 2003 Aug; 9(8):CS80-7. PubMed ID: 12942037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis.
    Kulkarni S; Naureckas E; Cronin DC
    Transplantation; 2003 Mar; 75(6):899-901. PubMed ID: 12660522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2011 Dec; 12(6):443-9. PubMed ID: 22185191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is worsening multiple organ failure the cause of death in patients with severe sepsis?
    Vincent JL; Nelson DR; Williams MD
    Crit Care Med; 2011 May; 39(5):1050-5. PubMed ID: 21317650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New and emerging therapies for sepsis.
    Healy DP
    Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic and organ dysfunction response during infusion of recombinant human activated protein C (rhAPC) in severe sepsis and septic shock.
    Gullo A; Iscra F; Di Capua G; Berlot G; Lucangelo U; Peratoner A; Fasiolo S; Viviani M; Consales C; Zicari A
    Minerva Anestesiol; 2005 Dec; 71(12):785-801. PubMed ID: 16288186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding events and mortality in SCT patients: a retrospective study of hematopoietic SCT patients with organ dysfunctions due to severe sepsis or GVHD.
    Holler E; Kolb HJ; Greinix H; Perrotin D; Campilho F; Aversa F; Gil L; Cornelissen J; Varanese L; Schacht A; Friese A; Rustige J
    Bone Marrow Transplant; 2009 Mar; 43(6):491-7. PubMed ID: 19079317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice].
    Dhainaut JF; Payen DM; Bernardin G; Gérard JL; Martin C; Perrotin D; Regnier B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():53-64. PubMed ID: 15359946
    [No Abstract]   [Full Text] [Related]  

  • 17. Activated recombinant protein C in septic shock early after liver transplantation: a case report.
    Feltracco P; Bortolato A; Rizzi S; Barbieri S; Furnari M; Serra E; Milevoj M; Ori C
    Transplant Proc; 2008; 40(6):2070-2. PubMed ID: 18675133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pasteurella multocida septic shock following liver transplantation treated with drotrecogin alpha (activated).
    Al-Sabah S; Goldberg P; Qureshi ST
    Transpl Infect Dis; 2007 Sep; 9(3):233-6. PubMed ID: 17692071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated protein C and septic shock: a propensity-matched cohort study*.
    Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
    Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
    Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
    Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.